A vaccine targeting mutant IDH1 induces antitumour immunity

By T. Schumacher, L. Bunse, S. Pusch, F. Sahm, B. Wiestler, Jasmin Quandt, O. Menn, Matthias Osswald, I. Oezen, Martina Ott and 17 more. Nature, 2014

677 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “1 3 specific for mutant IDH1/2 appears to be a practical lead for molecularly driven therapies and show promising preclinical results, either as a small molecular inhibitor or as a vaccine approach targeting the R132H protein as a tumorspecific neoantigen [135, 144].”
PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “As somatic genetic mutations could generate unique tumor-specific neoantigens and neoantigen-specific T cell responses (148), vaccination with immunogenic neoantigens has been examined in animal models (81, 82, 89).”
Glioma Subclassifications and Their Clinical Significance (2017, background): “Strategies include directly targeting IDH through small molecular IDH inhibitors or IDH-targeted vaccines [97].”